Pliva hosts R&D day in London
in London. The company says that it plans to update investors and
analysts alike on the recent developments in the company's R&D
pipeline.
Radan Spaventi, Vice President of Pliva's management board and CSO, says that he is "pleased that Pliva is continuing to deliver upon the promises made to investors. The progress shown in our R&D pipeline clearly shows that Pliva is successfully developing a wide range of generic, specialty and NCE products". He added: "We believe this strong pipeline will ensure sustainable growth as well as the transition to a non-azithromycin dependent business by 2006."
The company claims that through the year, it has proved its competence in the development of generics and specialty products and effective value chain integration. The company claims that 2003 has been an important year for the company.
Pliva continued to maintain its high level of R&D productivity, which has averaged over 500 submissions annually. This year brought the first wave of approvals across the CEE and Western Europe regions, for the company. The company says that these approvals validated Pliva's generics stategy. The company is expected to announce that it expects an increase in the number of submissions in the US in upcoming years.
From January through to November 2003, Pliva submitted 590 applications globally, consisting of 30 molecules or 105 products.
Pliva is also expected to announce the plans within its NCE and specialty pharmaceuticals.
Zelmir Vuksiic, vice-president of Pliva's management board and president of pharmaceuticals said:
"With our third quarter results, our pharmaceutical business clearly showed that Pliva began to deliver the organic growth that investors have been expecting from us. With over 700 registrations pending market approval, and more than 60 molecules continuosly in development, we believe that we will only continue to prove our strategy a success in the future."
